Association of polymorphisms in the TLR4 gene with the risk of developing neutropenia in children with leukemia

Leukemia

Volumn 25, Issue 6, 2011, Pages 995-1000

  Miedema, K G E ^a   Te Poele, E M ^a   Tissing, W J E ^a   Postma, D S ^b   Koppelman, G H ^a   De Pagter, A P ^c   Kamps, W A ^a   Alizadeh, B Z ^b   Boezen, H M ^b   De Bont, E S J M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

children; neutropenia; polymorphisms; TLR4

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; TOLL LIKE RECEPTOR 4;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER MORTALITY; CHILD; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INFANT; INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEUTROPENIA; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFANT; NEUTROPENIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TOLL-LIKE RECEPTOR 4;

EID: 79958154342     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.27     Document Type: Article

References (35)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64: 328-340.
2. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997; 99: 580-588.
3. Cairo MS. Dose reductions and delays: limitations of myelosuppressive chemotherapy. Oncology (Williston Park) 2000; 14: 21-31.
4. Stabell N, Nordal E, Stensvold E, Gammelsrud KW, Lund B, Taxt A et al. Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome. Scand J Infect Dis 2008; 40: 301-307. (Pubitemid 351447992)
5. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 2005; 103: 1916-1924. (Pubitemid 40563265)
6. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 2006; 12: 5481-5490. (Pubitemid 44497264)
7. Di Maio M, Gridelli C, Gallo C, Shepherd F, Piantedosi FV, Cigolari S et al. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of three randomised trials. Lancet Oncol 2005; 6: 669-677. (Pubitemid 41222757)
8. Chessells JM, Harrison G, Lilleyman JS, Bailey CC, Richards SM. Continuing (maintenance) therapy in lymphoblastic leukaemia: lessons from MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 1997; 98: 945-951.
9. Haslett C, Savill JS, Whyte MK, Stern M, Dransfield I, Meagher LC. Granulocyte apoptosis and the control of inflammation. Philos Trans R Soc Lond B Biol Sci 1994; 345: 327-333.
10. Dick EP, Prince LR, Prestwich EC, Renshaw SA, Whyte MK, Sabroe I. Pathways regulating lipopolysaccharide-induced neutrophil survival revealed by lentiviral transduction of primary human neutrophils. Immunology 2009; 127: 249-255.
11. Parker LC, Whyte MK, Dower SK, Sabroe I. The expression and roles of Toll-like receptors in the biology of the human neutrophil. J Leukoc Biol 2005; 77: 886-892. (Pubitemid 40770839)
12. Sabroe I, Prince LR, Jones EC, Horsburgh MJ, Foster SJ, Vogel SN et al. Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J Immunol 2003; 170: 5268-5275. (Pubitemid 36554761)
13. Francois S, El Benna J, Dang PM, Pedruzzi E, Gougerot-Pocidalo MA, Elbim C. Inhibition of neutrophil apoptosis by TLR agonists in whole blood: involvement of the phosphoinositide 3-kinase/Akt and NF-kappaB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad. J Immunol 2005; 174: 3633-3642. (Pubitemid 40354073)
14. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003; 102: 2660-2669. (Pubitemid 37193610)
15. McGettrick AF, O'Neill LA. Toll-like receptors: key activators of leucocytes and regulator of haematopoiesis. Br J Haematol 2007; 139: 185-193. (Pubitemid 47493098)
16. Klein JB, Buridi A, Coxon PY, Rane MJ, Manning T, Kettritz R et al. Role of extracellular signal-regulated kinase and phosphatidylinositol- .3. kinase in chemoattractant and LPS delay of constitutive neutrophil apoptosis. Cell Signal 2001; 13: 335-343. (Pubitemid 32448951)
17. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162: 3749-3752. (Pubitemid 29314747)
18. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor- .4. complex. J Immunol 2000; 164: 558-561. (Pubitemid 30043672)
19. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167: 2887-2894. (Pubitemid 32768923)
20. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999; 45: 7-17. (Pubitemid 29036378)
21. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death-a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-2632. (Pubitemid 41434385)
22. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3: 221-227.
23. Choi M, Rolle S, Wellner M, Cardoso MC, Scheidereit C, Luft FC et al. Inhibition of NF-kappaB by a TAT-NEMO-binding domain peptide accelerates constitutive apoptosis and abrogates LPS-delayed neutrophil apoptosis. Blood 2003; 102: 2259-2267. (Pubitemid 37122408)
24. Ward C, Chilvers ER, Lawson MF, Pryde JG, Fujihara S, Farrow SN et al. NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro. J Biol Chem 1999; 274: 4309-4318.
25. Schwartz DA. TLR4 and LPS hyporesponsiveness in humans. Int J Hyg Environ Health 2002; 205: 221-227. (Pubitemid 34475566)
26. Werner M, Topp R, Wimmer K, Richter K, Bischof W, Wjst M et al. TLR4 gene variants modify endotoxin effects on asthma. J Allergy Clin Immunol 2003; 112: 323-330. (Pubitemid 36981372)
27. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-191. (Pubitemid 30394990)
28. Schwartz DA. The genetics of innate immunity. Chest 2002; 121: 62S-68S. (Pubitemid 34248346)
29. Veerman AJ, Hahlen K, Kamps WA, Van Leeuwen EF, De Vaan GA, Solbu G et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996; 14: 911-918.
30. Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bökkerink JP, Bruin MC et al. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). Lancet Oncol 2009; 10: 957-966.
31. Kamps WA, Bokkerink JP, Hahlen K, Hermans J, Riehm H, Gadner H et al. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991). Blood 1999; 94: 1226-1236. (Pubitemid 29380403)
32. Kamps WA, Bokkerink JP, Hakvoort-Cammel FG, Veerman AJ, Weening RS, van Wering ER et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002; 16: 1099-1111. (Pubitemid 34624558)
33. Meulenbelt I, Droog S, Trommelen GJ, Boomsma DI, Slagboom PE. High-yield noninvasive human genomic DNA isolation method for genetic studies in geographically dispersed families and populations. Am J Hum Genet 1995; 57: 1252-1254.
34. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811-818. (Pubitemid 20343989)
35. Shalhub S, Junker CE, Imahara SD, Mindrinos MN, Dissanaike S, O'Keefe GE. Variation in the TLR4 gene influences the risk of organ failure and shock posttrauma: a cohort study. J Trauma 2009; 66: 115-122.